[go: up one dir, main page]

WO2002003992A3 - Therapie pour degenerescence osseuse en rapport avec une prothese - Google Patents

Therapie pour degenerescence osseuse en rapport avec une prothese Download PDF

Info

Publication number
WO2002003992A3
WO2002003992A3 PCT/US2001/021084 US0121084W WO0203992A3 WO 2002003992 A3 WO2002003992 A3 WO 2002003992A3 US 0121084 W US0121084 W US 0121084W WO 0203992 A3 WO0203992 A3 WO 0203992A3
Authority
WO
WIPO (PCT)
Prior art keywords
treating
alkyl
prosthesis
formulae
substituted indole
Prior art date
Application number
PCT/US2001/021084
Other languages
English (en)
Other versions
WO2002003992A2 (fr
Inventor
Simon Nicholas Jenkins
Barry Samuel Komm
Christopher Paul Miller
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Priority to AU2001271784A priority Critical patent/AU2001271784A1/en
Publication of WO2002003992A2 publication Critical patent/WO2002003992A2/fr
Publication of WO2002003992A3 publication Critical patent/WO2002003992A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette invention concerne des méthodes de traitement d'une dégénérescence osseuse en rapport avec une prothèse. Ces méthodes consistent à administrer un composé représenté par la formule (I) ou (II), ou un sel acceptable de ce composé, ou, éventuellement, un oestrogène. Dans la formule (I) ou (II), Z est une fraction prise dans le groupe de formules (a, b ou c) dans lequel: R1 est pris dans H, OH ou les esters en C1-C12 ou des alkyl éthers en C1-C12, ou des halogènes ; ou des éthers halogénés en C1-C4 comprenant un trifluorométhyl éther et un trichlorométhyl éther; R2, R3, R4, R5, et R6 sont H, OH ou des esters en C1-C12 ou des alkyl éthers en C1-C12, des halogènes, ou des éthers halogénés en C1-C4, cyano, alkyle en C1-C6, ou trifluorométhyle, à condition que, quand R1 est H, R2 N'est pas OH; Y est la fraction de la formule (d), R7 et R8 sont un alkyle ou sont concaténés pour former un noyau renfermant de l'azote éventuellement substitué.
PCT/US2001/021084 2000-07-06 2001-06-29 Therapie pour degenerescence osseuse en rapport avec une prothese WO2002003992A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001271784A AU2001271784A1 (en) 2000-07-06 2001-06-29 Therapy for prosthesis-related bone degeneration

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US21640600P 2000-07-06 2000-07-06
US21640700P 2000-07-06 2000-07-06
US60/216,407 2000-07-06
US60/216,406 2000-07-06

Publications (2)

Publication Number Publication Date
WO2002003992A2 WO2002003992A2 (fr) 2002-01-17
WO2002003992A3 true WO2002003992A3 (fr) 2002-06-27

Family

ID=26910981

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/021084 WO2002003992A2 (fr) 2000-07-06 2001-06-29 Therapie pour degenerescence osseuse en rapport avec une prothese

Country Status (2)

Country Link
AU (1) AU2001271784A1 (fr)
WO (1) WO2002003992A2 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1531807A4 (fr) * 2002-06-13 2007-10-31 Wyeth Corp Schemas therapeutiques du bazedoxifene
AU2003259220C1 (en) 2002-07-24 2017-08-24 Australian Health & Nutrition Association Limited Compositions and products containing enantiomeric equol, and methods for their making
US8668914B2 (en) 2002-07-24 2014-03-11 Brigham Young University Use of equol for treating skin diseases
JP4889944B2 (ja) 2002-10-29 2012-03-07 コロラド ステート ユニバーシティー リサーチ ファウンデーション アンドロゲンによって仲介される疾患を治療するためのエクオールの使用
US8580846B2 (en) 2002-10-29 2013-11-12 Brigham Young University Use of equol for ameliorating or preventing neuropsychiatric and neurodegenerative diseases or disorders
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
JO3112B1 (ar) 2010-03-29 2017-09-20 Ferring Bv تركيبة دوائية سريعة التحلل
KR101790188B1 (ko) 2010-03-29 2017-10-25 훼링 비.브이. 속용성 약학 조성물
US10292971B2 (en) 2015-10-01 2019-05-21 Olema Pharmaceuticals, Inc. Tetrahydro-1H-pyrido[3,4-b]indole anti-estrogenic drugs
ES2935125T3 (es) 2015-12-09 2023-03-01 Univ Illinois Reguladores a la baja selectivos de los receptores de estrógenos con base en benzotiofeno
WO2017197046A1 (fr) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Dégronimères de type glutarimide liés au carbone c3 pour la dégradation de protéines cibles
ES2990061T3 (es) 2016-05-10 2024-11-28 C4 Therapeutics Inc Degronímeros espirocíclicos para la degradación de proteínas diana
WO2017197051A1 (fr) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Dégronimères de c3-glutarimide liés à une amine pour la dégradation de protéines cibles
WO2017197055A1 (fr) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Dégronimères hétérocycliques pour la dégradation de protéines cibles
BR112018077136A2 (pt) 2016-07-01 2019-04-30 G1 Therapeutics, Inc. composto, e, métodos para tratar um distúrbio associado com proliferação celular anormal e para reduzir o efeito de quimioterapia em células saudáveis.
WO2018081168A2 (fr) 2016-10-24 2018-05-03 The Board Of Trustees Of The University Of Illinois Répresseurs du récepteur oestrogénique sélectifs mixtes à base de benzothiophène
IL267795B2 (en) 2017-01-06 2023-02-01 G1 Therapeutics Inc Combination therapy for the treatment of cancer
CA3052810A1 (fr) 2017-02-10 2018-08-16 G1 Therapeutics, Inc. Modulateurs du recepteur des ƒstrogenes de benzothiophene
CN110769822A (zh) 2017-06-20 2020-02-07 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
CA3067873A1 (fr) 2017-06-29 2019-01-03 G1 Therapeutics, Inc. Formes morphiques de g1t38 et leurs procedes de fabrication
EP3897631A4 (fr) 2018-12-20 2022-11-23 C4 Therapeutics, Inc. Dégradation ciblée de protéines
EP3993785A4 (fr) 2019-07-07 2023-08-02 Olema Pharmaceuticals, Inc. Régimes d'antagonistes du récepteur des oestrogènes
EP4076450A4 (fr) 2019-12-20 2024-01-10 C4 Therapeutics, Inc. Composés d'isoindolinone et d'indazole pour la dégradation de l'egfr
EP4114392A4 (fr) 2020-03-05 2024-04-10 C4 Therapeutics, Inc. Composés pour la dégradation ciblée de la brd9
CA3188313A1 (fr) 2020-08-05 2022-02-10 C4 Therapeutics, Inc. Composes pour la degradation ciblee de ret
WO2024030968A1 (fr) 2022-08-03 2024-02-08 Brystol-Myers Squibb Company Composés pour moduler la protéine ret
CN120569388A (zh) 2022-11-04 2025-08-29 百时美施贵宝公司 Ret-ldd蛋白降解剂
CN120530116A (zh) 2022-11-04 2025-08-22 百时美施贵宝公司 Ret-ldd蛋白抑制剂
WO2025006753A2 (fr) 2023-06-30 2025-01-02 Merck Patent Gmbh Composés hétérobifonctionnels pour la dégradation de la protéine kras

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996005824A1 (fr) * 1994-08-22 1996-02-29 Eli Lilly And Company Procedes enrayant la degenerescence des protheses osseuses
EP0802183A1 (fr) * 1996-04-19 1997-10-22 American Home Products Corporation Composés oestrogènes
EP0802184A1 (fr) * 1996-04-19 1997-10-22 American Home Products Corporation N-Benzyl-2-phénylindoles comme agents estrogènes
US5880137A (en) * 1996-04-19 1999-03-09 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
WO1999059581A1 (fr) * 1998-05-15 1999-11-25 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole en combinaison avec des oestrogenes
WO1999059969A1 (fr) * 1998-05-15 1999-11-25 American Home Products Corporation Compositions comprenant des composes a base de 2-phenyl-indole et de formulations d'oestrogenes
EP1123717A2 (fr) * 2000-01-26 2001-08-16 Pfizer Products Inc. Compositions contenant des agoniste-antagonistes d' oestrogène et une statine pour le traitement de l'ostéoporose et pour diminuer la valeur du choléstérol dans le sang

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996005824A1 (fr) * 1994-08-22 1996-02-29 Eli Lilly And Company Procedes enrayant la degenerescence des protheses osseuses
EP0802183A1 (fr) * 1996-04-19 1997-10-22 American Home Products Corporation Composés oestrogènes
EP0802184A1 (fr) * 1996-04-19 1997-10-22 American Home Products Corporation N-Benzyl-2-phénylindoles comme agents estrogènes
US5880137A (en) * 1996-04-19 1999-03-09 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
WO1999059581A1 (fr) * 1998-05-15 1999-11-25 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole en combinaison avec des oestrogenes
WO1999059969A1 (fr) * 1998-05-15 1999-11-25 American Home Products Corporation Compositions comprenant des composes a base de 2-phenyl-indole et de formulations d'oestrogenes
EP1123717A2 (fr) * 2000-01-26 2001-08-16 Pfizer Products Inc. Compositions contenant des agoniste-antagonistes d' oestrogène et une statine pour le traitement de l'ostéoporose et pour diminuer la valeur du choléstérol dans le sang

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE DRUGNL [online] "TSE 424", XP002195073, retrieved from STN Database accession no. 2000:1286 *
R&D FOCUS DRUG NEWS, 17 April 2000 (2000-04-17) *

Also Published As

Publication number Publication date
WO2002003992A2 (fr) 2002-01-17
AU2001271784A1 (en) 2002-01-21

Similar Documents

Publication Publication Date Title
WO2002003992A3 (fr) Therapie pour degenerescence osseuse en rapport avec une prothese
WO2002003986A3 (fr) Methodes de traitement des troubles mammaires
WO2002003976A3 (fr) Combinaisons de bisphosphonates, de substances a action oestrogenique et eventuellement d'oestrogenes
WO2002003991A3 (fr) Methodes permettant d'accroitre l'activite d'oxyde nitrique- synthase
WO2002003977A3 (fr) Combinaisons de statines, d'agents oestrogeniques et eventuellement d'oestrogenes
WO2002003988A3 (fr) Methodes permettant de traiter de troubles associes au neuropeptide y -
WO2002003990A3 (fr) Traitement d'une tension intra-oculaire excessive
WO2002003989A3 (fr) Therapie permettant d'inhiber l'incontinence du sphincter
WO2002003987A3 (fr) Compositions pharmaceutiques d'agents oestrogeniques
WO2002004418A3 (fr) Methodes permettant d'inhiber les effets uterotropes d'agents oestrogeniques
CO5550421A2 (es) Derivados de indol utiles para el tratamiento de enfermeda- des
DK1299348T3 (da) Forbindelser og sammensætninger til levering af aktive midler
NO20024891L (no) Farmasöytiske sammensetninger
EP1361220A4 (fr) Composes cycliques presentant un agonisme envers le recepteur de thrombopoietine
CA2372560A1 (fr) Cyanopyrroles pour la liaison de recepteur de progesterone
MXPA05008364A (es) Derivados de pirimidina para la prevencion de una infeccion por vih.
AU2001245972A1 (en) N-heterocyclic derivatives as nos inhibitors
EP1040823A3 (fr) Formulations de mousse stabiles
PE20080689A1 (es) Derivados de amina inhibidores de quinasa
AP2001002302A0 (en) 13-Methyl erythromycin derivatives.
EP1057819A4 (fr) Derives de phtalazine et remedes contre la dyserection
MY136824A (en) Substituted benzoxazinones and uses thereof
EP1277744A4 (fr) Derives d'oxadiazole efficaces en matiere de traitement ou de prevention d'etats pathologiques glomerulaires
MY138826A (en) 2,7-substituted indoles
NZ516100A (en) Streptogramin derivatives, preparation and compositions containing them

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP